[go: up one dir, main page]

CY1122646T1 - Δικυκλικες ετεροαρυλ ενωσεις - Google Patents

Δικυκλικες ετεροαρυλ ενωσεις

Info

Publication number
CY1122646T1
CY1122646T1 CY20191101304T CY191101304T CY1122646T1 CY 1122646 T1 CY1122646 T1 CY 1122646T1 CY 20191101304 T CY20191101304 T CY 20191101304T CY 191101304 T CY191101304 T CY 191101304T CY 1122646 T1 CY1122646 T1 CY 1122646T1
Authority
CY
Cyprus
Prior art keywords
bicyclic heteroaryl
heteroaryl compounds
compounds
preparation
general formula
Prior art date
Application number
CY20191101304T
Other languages
English (en)
Inventor
Dong Zou
Chester A. Metcalf, Iii
David C Dalgarno
Tomi K. Sawyer
Wei-Sheng Huang
R. Mathew Thomas
Jan Antoinette C. Romero
Jiwei Qi
Yihan Wang
Xiaotian Zhu
William C. Shakespeare
Rajeswari Sundaramoorthi
Original Assignee
Ariad Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122646(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharmaceuticals, Inc. filed Critical Ariad Pharmaceuticals, Inc.
Publication of CY1122646T1 publication Critical patent/CY1122646T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αυτή η εφεύρεση αναφέρεται σε ενώσεις του γενικού τύπου (I), στον οποίο οι μεταβλητές ομάδες είναι, όπως ορίζονται στην παρούσα, καθώς και στην παρασκευή και χρήση αυτών.
CY20191101304T 2005-12-23 2019-12-11 Δικυκλικες ετεροαρυλ ενωσεις CY1122646T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75396205P 2005-12-23 2005-12-23
US75400005P 2005-12-23 2005-12-23
US75608906P 2006-01-03 2006-01-03
US79847206P 2006-05-08 2006-05-08
US83319106P 2006-07-25 2006-07-25
PCT/US2006/048758 WO2007075869A2 (en) 2005-12-23 2006-12-22 Bicyclic heteroaryl compounds
EP06845939A EP1973545B1 (en) 2005-12-23 2006-12-22 Bicyclic heteroaryl compounds

Publications (1)

Publication Number Publication Date
CY1122646T1 true CY1122646T1 (el) 2020-10-14

Family

ID=38218600

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20131100091T CY1113907T1 (el) 2005-12-23 2013-01-31 Δικυκλικες ετεροαρυλ ενωσεις
CY2013044C CY2013044I2 (el) 2005-12-23 2013-12-06 Δικυκλικες ετεροαρυλ ενωσεις
CY20191101304T CY1122646T1 (el) 2005-12-23 2019-12-11 Δικυκλικες ετεροαρυλ ενωσεις

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20131100091T CY1113907T1 (el) 2005-12-23 2013-01-31 Δικυκλικες ετεροαρυλ ενωσεις
CY2013044C CY2013044I2 (el) 2005-12-23 2013-12-06 Δικυκλικες ετεροαρυλ ενωσεις

Country Status (20)

Country Link
US (9) US8114874B2 (el)
EP (4) EP3747441A1 (el)
JP (3) JP5200939B2 (el)
KR (1) KR101436303B1 (el)
CN (1) CN103044432B (el)
AU (1) AU2006331673B2 (el)
CA (1) CA2634923C (el)
CY (3) CY1113907T1 (el)
DK (2) DK2495016T3 (el)
EA (2) EA034598B1 (el)
ES (2) ES2761180T3 (el)
HU (2) HUE047422T2 (el)
IL (2) IL191938A (el)
LT (1) LT2495016T (el)
LU (1) LU92327I2 (el)
MX (2) MX343042B (el)
PL (2) PL1973545T3 (el)
PT (2) PT2495016T (el)
SI (1) SI2495016T1 (el)
WO (1) WO2007075869A2 (el)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
ES2761180T3 (es) 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
CN103467385B (zh) * 2006-05-08 2016-03-09 阿里亚德医药股份有限公司 单环杂芳基化合物
CN103435595A (zh) 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
JP2010510242A (ja) 2006-11-16 2010-04-02 アラーガン、インコーポレイテッド キナーゼ阻害剤としてのスルホキシミン
RS52677B (en) 2006-11-22 2013-06-28 Incyte Corporation IMIDAZOTRIAZINI I IMIDAZOPIRIMIDINI KAO INHIBITORI KINAZE
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
BRPI0912882A2 (pt) 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
FR2933981A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
US8455477B2 (en) * 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
WO2010056311A1 (en) 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
WO2011053938A1 (en) * 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
CA2784807C (en) * 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
US8846671B2 (en) 2010-07-01 2014-09-30 Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
CN101885722B (zh) * 2010-07-01 2013-07-24 中国科学院广州生物医药与健康研究院 杂环炔苯类化合物及其药用组合物和应用
JP5905028B2 (ja) * 2011-01-21 2016-04-20 スン プハルマ アドバンセド リサーチ カンパニー リミテド ジアリールアセチレンヒドラジドを含有するチロシンキナーゼ阻害剤
WO2012127030A1 (en) * 2011-03-23 2012-09-27 Proteosys Ag Arylpiperazines as neuroprotective agents
KR20140022063A (ko) * 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 신경 변성 질환을 치료하기 위한 방법 및 조성물
EA201391486A1 (ru) * 2011-04-07 2014-09-30 Ариад Фармасьютикалз, Инк. Способы и композиции для лечения болезни паркинсона
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013162727A1 (en) * 2012-04-25 2013-10-31 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
WO2013170774A1 (zh) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
US20150291594A1 (en) * 2012-08-14 2015-10-15 Concert Pharmaceuticals, Inc. Deuterated Ponatinib
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
CN103848829B (zh) 2012-11-28 2017-04-12 南京圣和药业股份有限公司 杂芳基炔烃化合物及其应用
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
EP2968276A4 (en) * 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
CA2916329A1 (en) * 2013-07-04 2015-01-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
GB2518873A (en) 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN104650086A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 盐酸帕纳替尼化合物
WO2015085971A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
WO2015085973A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt
WO2015085972A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9765072B2 (en) 2014-06-06 2017-09-19 Natco Pharma Limited 1H-1,8-naphthyridin-2ones as anti proliferative compounds
DK3169671T3 (da) 2014-07-17 2019-09-23 Sunshine Lake Pharma Co Ltd 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
CN105837575B (zh) * 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106167491A (zh) * 2015-05-19 2016-11-30 重庆大学 一种有效抑制肺癌转移的化合物及其应用
WO2016201203A1 (en) * 2015-06-11 2016-12-15 Apicore Us Llc Processes for making ponatinib and intermediates thereof
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
BR112018004585A2 (pt) * 2015-09-09 2018-09-25 C. Lau Warren métodos, composições e usos de inibidores da fyn quinase
US20170252350A1 (en) 2016-03-03 2017-09-07 Cornell University Small molecule ire1-alpha inhibitors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2017222285A1 (ko) * 2016-06-20 2017-12-28 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다조피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US20210006178A1 (en) * 2016-09-29 2021-01-07 Transportation Ip Holdings, Llc Harmonic distortion reduction system for converters connected to a common bus
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
AU2018235446B2 (en) 2017-03-15 2022-04-07 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of 4-Methyl-3-quinolin-3-ylethynyl-benzoic acid N'-(2-chloro-6-methyl-benzoyl) hydrazide
CN110506036A (zh) * 2017-03-15 2019-11-26 太阳制药先进研究有限公司 环丙烷羧酸(5-{5-[n′-(2-氯-6-甲基苯甲酰基)肼基羰基]-2-甲基-苯基乙炔基}-吡啶-2-基)酰胺的新型无定形分散体
US11072620B2 (en) 2017-06-20 2021-07-27 Apotex Inc. Crystalline forms of Ponatinib hydrochloride
JP7024960B2 (ja) * 2017-10-04 2022-02-24 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
EP3781568A1 (en) 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
WO2020007234A1 (zh) * 2018-07-02 2020-01-09 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基(杂)芳环类化合物
CN110272426B (zh) * 2018-07-17 2022-05-31 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
WO2020053812A1 (en) * 2018-09-12 2020-03-19 Purdue Research Foundation Alkynyl nicotinamide compounds as kinase inhibitors
WO2020079652A1 (en) 2018-10-17 2020-04-23 Insilico Medicine Hong Kong Limited Kinase inhibitors
MX2021005011A (es) 2018-11-01 2021-07-21 Syros Pharmaceuticals Inc Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2020214999A1 (en) * 2019-04-17 2020-10-22 Emory University Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
KR102205619B1 (ko) 2019-06-12 2021-01-21 한국과학기술연구원 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
EP4175957A4 (en) * 2020-06-24 2024-06-26 Purdue Research Foundation 2,3-DISUBSTITUTED PYRIDO[3,4-B!PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US20220289756A1 (en) * 2021-03-11 2022-09-15 Wai Kit Pang Compounds and compositions as inhibitors of protein kinases
CN112778207A (zh) * 2021-03-19 2021-05-11 海南鑫开源医药科技有限公司 一种盐酸尼洛替尼原料药杂质及其制备方法
AU2021440841A1 (en) 2021-04-13 2023-10-19 Shenzhen Newdel Biotech Co., Ltd. Alkynylphenylbenzamide compound and use thereof
WO2022225972A1 (en) * 2021-04-19 2022-10-27 Oregon Health & Science University Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders
IL312506A (en) 2021-11-08 2024-07-01 Progentos Therapeutics Inc Platelet-based alpha inhibitors and their uses
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
TW202434233A (zh) * 2023-01-13 2024-09-01 大陸商深圳市新樾生物科技有限公司 化合物a的鹽和晶型、其製備方法和用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5099057A (en) 1987-10-19 1992-03-24 The Dow Chemical Company Process for the preparation of ar-amino-para-arenediols
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
ATE117690T1 (de) 1990-03-01 1995-02-15 Takeda Chemical Industries Ltd Imidazopyridazine, ihre herstellung und verwendung.
ATE208778T1 (de) 1995-05-09 2001-11-15 Basf Ag Pyrazolo- 1,5a)-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
ATE298325T1 (de) 1999-11-08 2005-07-15 Schering Corp Verfahren zur herstellung von n-(4-hydroxyphenyl)-n'-(4'-aminophenyl)-piperaz ne
WO2001053298A1 (en) 2000-01-18 2001-07-26 Neurogen Corporation Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
EP1301511A2 (en) 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10117183A1 (de) 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
DE10117184A1 (de) 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
WO2002096933A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
IL159811A0 (en) * 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
WO2003022850A1 (fr) 2001-09-04 2003-03-20 Sumitomo Chemical Company, Limited Imidazo[1, 2-a] pyrimidines et compositions fongicides les contenant
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
CN100537571C (zh) 2002-04-19 2009-09-09 细胞基因组公司 咪唑并[1,2-а]吡嗪-8-基胺,其制备方法及使用方法
WO2003103658A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
AU2003252509A1 (en) 2002-07-29 2004-02-16 Sumitomo Chemical Takeda Agro Company, Limited NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-b)PYRIDAZINE DERIVATIVE
EP1536729B1 (en) 2002-09-11 2012-03-21 Becton Dickinson and Company Monitoring blood glucose including convenient display of measurement values and averages
DE10246890A1 (de) 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
TW200418466A (en) * 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
BRPI0414778A (pt) 2003-09-24 2006-11-21 Wyeth Corp 6-aril-7-halo-imidazo[1,2-a]pirimidinas como agentes anticáncer
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
RU2006122853A (ru) 2003-11-28 2008-01-10 Новартис АГ (CH) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
EP1694691A1 (en) 2003-12-05 2006-08-30 Biovitrum Ab Improved synthesis of 2-substituted adenosines
ES2317079T3 (es) * 2003-12-24 2009-04-16 Astrazeneca Ab Pirimidinas con actividad tie2 (tek).
ATE402705T1 (de) * 2003-12-24 2008-08-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
EA011930B1 (ru) * 2004-04-07 2009-06-30 Лаборатуар Сероно Са Карбоновые кислоты
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
JP2008506702A (ja) * 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
JP4801724B2 (ja) * 2005-03-23 2011-10-26 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのアセチレニル−ピラゾロ−ピリミジン誘導体
EP1893605A2 (en) 2005-03-31 2008-03-05 AstraZeneca AB Saminopyrimidine derivates with tie2 inhibiting activity
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
ES2761180T3 (es) 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
CN103435595A (zh) 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
CN103467385B (zh) * 2006-05-08 2016-03-09 阿里亚德医药股份有限公司 单环杂芳基化合物
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US20100273772A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
US8461851B2 (en) 2009-06-08 2013-06-11 University Of Hawaii Systems for transverse electromagnetic mode in-situ soil testing
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011053938A1 (en) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
KR20140022063A (ko) 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 신경 변성 질환을 치료하기 위한 방법 및 조성물
JP5300939B2 (ja) * 2011-08-25 2013-09-25 安田工業株式会社 仕上加工用工具を用いた加工方法
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
WO2007075869A2 (en) 2007-07-05
HUS1300078I1 (hu) 2018-11-28
US9278971B2 (en) 2016-03-08
EA027573B1 (ru) 2017-08-31
PT2495016T (pt) 2019-12-16
US20130196979A1 (en) 2013-08-01
MX2008008152A (es) 2008-09-12
US8778942B2 (en) 2014-07-15
US20190031656A1 (en) 2019-01-31
PL2495016T3 (pl) 2020-06-01
US20070191376A1 (en) 2007-08-16
IL191938A0 (en) 2009-08-03
CN103044432B (zh) 2016-08-03
CY1113907T1 (el) 2015-11-04
IL191938A (en) 2016-03-31
BRPI0621098A2 (pt) 2013-04-02
DK1973545T3 (da) 2013-02-25
LU92327I2 (fr) 2014-02-05
US20220081440A1 (en) 2022-03-17
LU92327I9 (el) 2019-01-16
EP3747441A1 (en) 2020-12-09
CA2634923A1 (en) 2007-07-05
US20160368917A1 (en) 2016-12-22
ES2761180T3 (es) 2020-05-19
EP3417912A1 (en) 2018-12-26
AU2006331673A1 (en) 2007-07-05
US20140288082A1 (en) 2014-09-25
US9029533B2 (en) 2015-05-12
US8114874B2 (en) 2012-02-14
EP1973545A4 (en) 2010-03-10
EP2495016B1 (en) 2019-10-16
MX343042B (es) 2016-10-21
CY2013044I1 (el) 2015-11-04
DK2495016T3 (da) 2019-12-16
JP6604739B2 (ja) 2019-11-13
HUE047422T2 (hu) 2020-04-28
LT2495016T (lt) 2020-02-10
CA2634923C (en) 2015-05-05
KR20080081191A (ko) 2008-09-08
US20200231588A1 (en) 2020-07-23
KR101436303B1 (ko) 2014-09-02
JP5790629B2 (ja) 2015-10-07
AU2006331673B2 (en) 2013-02-28
EP1973545B1 (en) 2013-01-30
EP3417912B1 (en) 2020-08-12
US20120135986A1 (en) 2012-05-31
ES2403206T3 (es) 2013-05-16
US20130231337A1 (en) 2013-09-05
JP2009521462A (ja) 2009-06-04
SI2495016T1 (sl) 2020-04-30
EA200870116A1 (ru) 2009-10-30
JP2015147796A (ja) 2015-08-20
EA201790678A1 (ru) 2017-12-29
IL239445A (en) 2017-02-28
JP2013064004A (ja) 2013-04-11
PT1973545E (pt) 2013-02-11
EA034598B1 (ru) 2020-02-25
PL1973545T3 (pl) 2013-05-31
US8470851B2 (en) 2013-06-25
JP5200939B2 (ja) 2013-06-05
CY2013044I2 (el) 2015-11-04
IL239445A0 (en) 2015-07-30
EP2495016A1 (en) 2012-09-05
EP1973545A2 (en) 2008-10-01
WO2007075869A3 (en) 2007-11-29
CN103044432A (zh) 2013-04-17

Similar Documents

Publication Publication Date Title
CY1122646T1 (el) Δικυκλικες ετεροαρυλ ενωσεις
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1120638T1 (el) Αναστολεις τυροσινικης κινασης πυριμιδινυλιου
CY1118346T1 (el) Αρυλoαζoλ-2-υλ κυανοαιθυλαμινο ενωσεις, μεθοδος κατασκευης και μεθοδος χρησης αυτων
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
CY1115321T1 (el) Αντισωματα κατευθυνομενα προς αγγειοποιητινη-1 και αγγειοποιητινη-2 και χρηση αυτων
CY1119006T1 (el) Ινδολια
CY1118860T1 (el) Νεα διαζασπειροκυκλοαλκανια και αζασπειροκυκλοαλκανια
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
CY1117767T1 (el) Rsv-ειδικα προσδενομενα μορια και μεσα για την παραγωγη αυτων
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
EA200870514A1 (ru) Ацетиленовые гетероарильные соединения
BRPI0817265A2 (pt) Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
ECSP10010722A (es) Compuestos orgánicos
EA200702347A1 (ru) Способ получения глюкопиранозилзамещённых производных бензилбензола и промежуточных продуктов для их получения
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
CY1119399T1 (el) Aντι-dkk-1 αντισωματα
CY1111154T1 (el) Ενωσεις ιμιδαζο (1,2-α) πυριδινης ως αναστολεις του vegf-r2
EA200701918A1 (ru) Белок липокалин
ECSP10010334A (es) Derivados de quinolina y su uso como fungicidas
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
EA200870515A1 (ru) Моноциклические гетероарильные соединения